author-photo

Artur Racewicz

15

Papers

1918

Citations

Citation Trend

Filter By

Papers (8) Sort By

Journal Conference Others

Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis

2018 Arthritis & Rheumatism
Show All
- Source
- Cite
- Save
Citations (67)
Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis

2018 Arthritis & Rheumatism
Show All
- Source
- Cite
- Save
Citations (71)
Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

2018 The Lancet
Show All
- Source
- Cite
- Save
Citations (111)
A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study

2016 Arthritis Research & Therapy
Show All
- Source
- Cite
- Save
Citations (128)
FRI0161 Sustained Efficacy and Comparable Safety and Immunogenicity after Transition To SB5 (An Adalimumab Biosimilar) vs Continuation of The Adalimumab Reference Product in Patients with Rheumatoid Arthritis: Result of Phase III Study

2016 Annals of the Rheumatic Diseases
Show All
- Source
- Cite
- Save
Citations (6)
OP0068 A Phase 3 Randomised Controlled Trial to Compare CT-P13 with Infliximab in Patients with Active Rheumatoid Arthritis: 54 Week Results from the Planetra Study

2013 Annals of the Rheumatic Diseases
Show All
- Source
- Cite
- Save
Citations (27)
Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: A phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study

2009 Clinical Therapeutics
Show All
- Source
- Cite
- Save
Citations (20)
Monthly dosing with risedronate 50 mg on three consecutive days a month compared with daily dosing with risedronate 5 mg: a 6-month pilot study

2007 Current Medical Research and Opinion
Show All
- Source
- Cite
- Save
Citations (5)